Article
Comparative effects of aprotinin and human recombinant R24K KD1 on temporal renal function in Long-Evans rats.
The Journal of pharmacology and experimental therapeutics - 1 Dec 2009
Kempaiah Prakasha, Danielson Leslie A, Barry Marc, Kisiel Walter
Abstract excerpt
Bovine aprotinin, a reversible inhibitor of plasmin and kallikrein, has been clinically approved for over two decades to prevent perioperative blood loss during cardiac surgery. However, because of postoperative renal dysfunction in thousands of these patients, aprotinin was voluntarily withdrawn from the market. Our earlier studies indicated that a R24K mutant of the first Kunitz-type domain of human tissue...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
